NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT1032230486

Registered date:03/12/2023

Not applicable

Basic Information

Recruitment status Not Recruiting
Health condition(s) or Problem(s) studiedType 2 diabetes
Date of first enrollment16/10/2023
Target sample size30
Countries of recruitment
Study typeObservational
Intervention(s)

Outcome(s)

Primary OutcomeResults of a survey on the use of the OneDra for patients with type 2 diabetes
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximumNot applicable
GenderBoth
Include criteriaPatients who meet all of the following criteria will be considered. 1) Age 18 years or older on the date of consent, regardless of gender 2) Outpatients with mild to moderate type 2 diabetes whose condition is stable 3) Patients who are able to adhere to medication adherence and diet and exercise regimen as directed 4) Patients with HbA1c less than 8.0% on the last 2 diabetes examinations prior to obtaining consent 5) Patients who have not changed their diabetes medications since the two previous visits at the time of obtaining consent and have no plans to do so until the end of this study 6) Patients who have received a thorough explanation of their participation in this study, and who have given written consent of their own free will based on sufficient understanding
Exclude criteriaPatients who violate the following criteria will be excluded from this study. 1) Patients with type I diabetes mellitus 2) Patients on insulin therapy 3) Patients who may exhibit severe ketosis, diabetic coma or pre-comatose state during study participation 4) Patients with unstable HbA1c levels 5) Patients with restrictions on diet and exercise due to other diseases or complications 6) Patients who are pregnant, lactating, may be pregnant, or are planning to become pregnant 7) Patients with impaired hemostatic function due to bleeding disorder or medication, or with shock or allergy 8) Other patients deemed by the physician to be ineligible for participation

Related Information

Contact

Public contact
Name Hashimoto Masaki
Address 7-1, Nihonbashi 2-chome, Chuo-ku, Tokyo 103-6012, Japan Tokyo Japan 103-6012
Telephone +81-3-5205-3720
E-mail fbo_ir@sumitomo-pharma.co.jp
Affiliation Sumitomo Pharma Co., Ltd.
Scientific contact
Name Hori Seiji
Address 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, Osaka 541-0045, Japan Osaka Japan 541-0045
Telephone +81-120-034-389
E-mail fbo_ir@sumitomo-pharma.co.jp
Affiliation Sumitomo Pharma Co., Ltd.